iPSC-Derived Microglia as a Model to Study Inflammation in Idiopathic Parkinson's Disease. by Badanjak, Katja et al.
fcell-09-740758 November 1, 2021 Time: 13:47 # 1
ORIGINAL RESEARCH




University Hospital Rostock, Germany
Reviewed by:
Qian Chen,
Warren Alpert Medical School







This article was submitted to
Stem Cell Research,
a section of the journal
Frontiers in Cell and Developmental
Biology
Received: 13 July 2021
Accepted: 08 October 2021
Published: 05 November 2021
Citation:
Badanjak K, Mulica P, Smajic S,
Delcambre S, Tranchevent L-C,
Diederich N, Rauen T,
Schwamborn JC, Glaab E,
Cowley SA, Antony PMA, Pereira SL,
Venegas C and Grünewald A (2021)
iPSC-Derived Microglia as a Model
to Study Inflammation in Idiopathic
Parkinson’s Disease.
Front. Cell Dev. Biol. 9:740758.
doi: 10.3389/fcell.2021.740758
iPSC-Derived Microglia as a Model to
Study Inflammation in Idiopathic
Parkinson’s Disease
Katja Badanjak1, Patrycja Mulica1, Semra Smajic1, Sylvie Delcambre1,
Leon-Charles Tranchevent1, Nico Diederich2, Thomas Rauen3, Jens C. Schwamborn1,
Enrico Glaab1, Sally A. Cowley4, Paul M. A. Antony1,5, Sandro L. Pereira1,
Carmen Venegas1 and Anne Grünewald1,6*
1 Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Luxembourg, Luxembourg, 2 Centre Hospitalier
de Luxembourg (CHL), Luxembourg, Luxembourg, 3 Department of Cell and Developmental Biology, Max Planck Institute
for Molecular Biomedicine, Münster, Germany, 4 James Martin Stem Cell Facility, Sir William Dunn School of Pathology,
University of Oxford, Oxford, United Kingdom, 5 Disease Modeling and Screening Platform (DMSP), Luxembourg Institute of
Systems Biomedicine, University of Luxembourg and Luxembourg Institute of Health, Luxembourg, Luxembourg, 6 Institute
of Neurogenetics, University of Lübeck, Lübeck, Germany
Parkinson’s disease (PD) is a neurodegenerative disease with unknown cause in the
majority of patients, who are therefore considered “idiopathic” (IPD). PD predominantly
affects dopaminergic neurons in the substantia nigra pars compacta (SNpc), yet the
pathology is not limited to this cell type. Advancing age is considered the main risk
factor for the development of IPD and greatly influences the function of microglia, the
immune cells of the brain. With increasing age, microglia become dysfunctional and
release pro-inflammatory factors into the extracellular space, which promote neuronal
cell death. Accordingly, neuroinflammation has also been described as a feature of PD.
So far, studies exploring inflammatory pathways in IPD patient samples have primarily
focused on blood-derived immune cells or brain sections, but rarely investigated patient
microglia in vitro. Accordingly, we decided to explore the contribution of microglia to IPD
in a comparative manner using, both, iPSC-derived cultures and postmortem tissue.
Our meta-analysis of published RNAseq datasets indicated an upregulation of IL10
and IL1B in nigral tissue from IPD patients. We observed increased expression levels
of these cytokines in microglia compared to neurons using our single-cell midbrain
atlas. Moreover, IL10 and IL1B were upregulated in IPD compared to control microglia.
Next, to validate these findings in vitro, we generated IPD patient microglia from
iPSCs using an established differentiation protocol. IPD microglia were more readily
primed as indicated by elevated IL1B and IL10 gene expression and higher mRNA
and protein levels of NLRP3 after LPS treatment. In addition, IPD microglia had higher
phagocytic capacity under basal conditions—a phenotype that was further exacerbated
upon stimulation with LPS, suggesting an aberrant microglial function. Our results
demonstrate the significance of microglia as the key player in the neuroinflammation
process in IPD. While our study highlights the importance of microglia-mediated
inflammatory signaling in IPD, further investigations will be needed to explore particular
disease mechanisms in these cells.
Keywords: microglia, iPSC, neuroinflammation, idiopathic Parkinson’s disease, disease modeling
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INTRODUCTION
Parkinson’s disease (PD) is an age-related, multifactorial disorder,
resulting in the demise of dopaminergic neurons in the substantia
nigra pars compacta (SNpc) of the midbrain, which subsequently
leads to motor difficulties, tremor, and postural instability in
affected individuals (Pang et al., 2019). While there is a genetic
component to the disease, with 10% of all cases carrying a
mutation in one of the causal PD genes, 90% of patients are
deemed idiopathic.
The majority of studies published to date describe molecular
mechanisms centered around α-synuclein aggregation,
mitochondrial dysfunction, dysregulated autophagy flux,
and neuroinflammation as the underlying causes of PD (Wang
et al., 2015; Maiti et al., 2017). Interestingly, all of these processes
are also affected by aging, which leads to functional decline, both
at the physiological and molecular level. Thus, it is not surprising
that aging is considered a major risk factor for the development
of PD (Jin et al., 2020).
Additionally, “inflammaging” is a novel term coined to define
basal, low-level inflammation during adult life that, with time,
turns into a destructive, pathological process. On the one
hand, lower levels of inflammation are considered to have a
positive outcome on the overall cellular state. On the other
hand, during prolonged inflammation, beneficial mechanisms
of defense start to wear off while damaging insults increase.
This phenomenon might explain why seemingly low-grade
inflammatory occurrences can have a significant negative impact
on health in older individuals (Calabrese et al., 2018).
Inflammation is one of the hallmarks of PD and it
is propagated mostly through microglia cells, which are
responsible for the innate immune defense of the brain. Early
brain tissue studies showed an upregulation of microglial
cells in the SNpc and higher expression of human major
histocompatibility complex class II (MHC-II) molecules, while
in human serum and cerebrospinal fluid (CSF), increased
concentrations of cytokines such as IL-1β, IL-6, TNF-α, IL-
2, IL-18, and, IL-10 were detected (Nagatsu and Sawada,
2005; Brodacki et al., 2008; Long-Smith et al., 2009; Collins
et al., 2012; Wang et al., 2015; Badanjak et al., 2021). In
line with these results, our own immunohistochemistry and
single-nuclei transcriptomic analyses in postmortem midbrain
tissue revealed an increase in abundance and a decrease in
the complexity of microglia in IPD tissue, suggestive of an
activated state. Moreover, patient microglia presented a disease-
specific gene expression signature, indicating a significant role
of these cells in the pathogenesis of the movement disorder
(Smajić et al., 2020). Also, most recently, genes of the IFN-γ
signaling pathway were found to be dysregulated in IPD patients
(Magalhaes et al., 2021).
One of the most commonly implicated inflammatory
pathways in PD is the inflammasome pathway (Chao et al.,
2014; Sebastian-Valverde and Pasinetti, 2020; Yan et al., 2020).
The NOD-, LRR-, and pyrin domain-containing protein 3
(NLRP3) is by far the most studied inflammasome, the main
function of which is the clearance of pathogens. NLRP3 is
a cytosolic sensor of intracellular and extracellular stimuli
such as damage-associated and pathogen-associated molecular
patterns (DAMPs and PAMPs, respectively). Two signals are
necessary to fully activate this pathway, a priming signal and
an activation signal. The priming signal is characterized by
the upregulation of IL1B and NLRP3 expression, while the
secondary signal is characterized by the release of mature
cytokines (Swanson et al., 2019). Underlining the relevance of the
NLRP3 inflammasome, IL-1β has been associated with disease
pathogenesis in multiple PD biomarker studies (Koprich et al.,
2008; Su et al., 2008; Nakahira et al., 2011; Gillardon et al., 2012;
Pike et al., 2021).
In our current study, we investigated inflammation markers
in different models of IPD. First, we explored available RNAseq
transcriptomic datasets from postmortem midbrain tissues to
assess the expression of key cytokines in IPD. Next, we
differentiated microglia from iPSC from IPD and control donors
to test whether these cells can mirror the phenotypes observed
in the brain. We detected elevated levels of IL1B and IL10 in
whole tissue or single cell RNAseq datasets from IPD nigral
or midbrain sections. Indicative of the fidelity of iPSC-derived
cellular PD models, both IL1B and IL10 were also upregulated
in patient microglia upon lipopolysaccharide (LPS) treatment.
This coincided with increased protein abundance of NLRP3
in these cells, further implicating the inflammasome in the
pathogenesis of PD.
MATERIALS AND METHODS
Bulk RNA Cytokine Expression Analysis
To profile the expression of cytokines in human SN tissue,
we used a differential expression meta-analysis of publicly
available case-control transcriptomics datasets, including only
SN samples, as previously described (Glaab and Schneider, 2015).
This provided meta-analysis Z-scores and FDR significance
scores for candidate genes of interest (see Supplementary
Table 1).
Postmortem Single-Nuclei RNA
Sequencing of Human Midbrain
To analyze cytokine expression in a single-cell landscape, in
this study, we used our previously published snRNAseq dataset
from five IPD and six control postmortem midbrain tissues
(GSE157783). The normalization, sample integration and cell
clustering were performed using Seurat (version 3.1.5) in R 4.0.0.,
as described in Smajić et al. (2020).
The gene expression analysis was performed in neuronal
and microglial clusters derived from our snRNAseq dataset
(Smajić et al., 2020). For each of the two clusters, pseudobulk
populations were created by merging all cells in the cluster
from every individual in order to present the overall expression
of cytokines. Then, the expression was presented as a sum
of expressions of each individual cell and displayed in a
bar plot using “ggplot2” and “gg.gap” packages. The cytokine
expression in microglia was shown in both conditions using the
“DotPlot” function.
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Differentiation of Human iPSCs Into
Microglia
An IPD patient as well as an age- and gender-matched
control (both female, age: 68; IPD patient AAO: 60), who
donated skin biopsies for the study, gave written and informed
consent. Skin fibroblasts were reprogrammed into iPSCs
as previously described (Arias-Fuenzalida et al., 2017). The
study was approved by the Comité National d’Ethique de
Recherche Luxembourg (CNER, vote 201411/05 V1.3). iPSCs
were maintained in mTeSRTM1 complete medium (StemCell
Technologies). Microglia were differentiated from iPSCs
following an established protocol (van Wilgenburg et al., 2013;
Haenseler et al., 2017). In brief, embryoid bodies (EBs) were
generated from iPSCs in mTeSR Plus (STEMCELL Technologies)
supplemented with 50 ng/ml BMP-4 (Invitrogen), 50 ng/ml
VEGF (Invitrogen) and 20 ng/ml SCF (Miltenyi). On day 4,
EBs were transferred to a low attachment 6-well plate and were
replenished with fresh EB media. On day 7, the medium was
changed to X-VIVO 15 (Lonza) supplemented with 25 ng/ml IL-
3 (Invitrogen), 100 ng/ml M-CSF (Invitrogen), 2 mM Glutamax
(Gibco), 1% P/S (Gibco) and 0.055 mM β-mercaptoethanol
(Gibco) and the EBs were transferred to T75 flasks (factories).
These conditions promoted the generation of macrophage
precursors. The factories were kept in culture for up to 6–
8 months and macrophage precursors were harvested regularly.
Terminal differentiation was achieved by culturing macrophage
precursors in advanced DMEM/F12 supplemented with N2,
Glutamax, P/S, β-mercaptoethanol, 100 ng/ml IL-34 (Peprotech)
and 10 ng/ml GM-CSF (Peprotech). During all steps of the
differentiation, cells were incubated at 37◦C, 5% CO2.
Microglia Treatments
Microglia were seeded into 6-well plates at a density of
1× 10ˆ6 cells/well. Upon treatment with 100 ng/ml LPS (Thermo
Fisher Scientific 00-4976-93) for 3 h, cells were subjected to
protein and RNA extractions. For functional analyses, microglia
were seeded into 96-well glass-bottom plates at a density
of 25,000 cells/well. Cells were treated with 50,000 Zymosan
bioparticles (Thermo Fisher Scientific) per well for 45 min.
After, cells were subjected to fixation (described in more
detail below).
RNA Isolation and Quantitative PCR
RNA was isolated from microglia using the RNeasy RNA
isolation kit (Qiagen, 74106) following the manufacturer’s
instructions for direct RNA extraction from the plate. cDNA
was synthesized from 200 ng of RNA using the SuperScriptTM
III Reverse Transcriptase (Invitrogen, 18080044). Quantitative
PCR (qPCR) was performed using iQ SYBR Green (Biorad,
170-8885). The PCR reaction was run on a LightCycler 480
(Roche). The samples were denatured for 5 min at 95◦C.
Amplification ran over 45 cycles with a denaturation step of
10 s at 95◦C, primer annealing of 10 s at 60◦C, and elongation
of 10 s at 75◦C. The expression of IL1B, IL10, LRRK2, and
NLRP3 was normalized to the expression of the housekeeping
gene ACTB.
Western Blotting
Total protein from microglia cultures were extracted directly
from the plate, using ice cold RIPA buffer (Pierce) supplemented
with 1X Protease/phosphatase Inhibitor Cocktail (Thermo Fisher
Scientific). The whole well was washed multiple times, on ice,
and the lysate suspension was transferred to an Eppendorf
tube and vortexed for 20 s followed by incubation on ice
for 20 min. The samples were centrifuged at 21,130 g for
20 min at 4◦C. The protein concentration of the cell lysates
was measured using a bicinchoninic acid assay using PierceTM
BCA protein kit (Thermo Fisher Scientific) following the
manufacturer’s instructions.
Cell lysates were denatured in a loading buffer at 95◦C for
5 min prior to loading on the gels. Proteins were then separated
on NuPAGE 4–12% Bis-Tris gels (Invitrogen) in NuPAGE
MES Running Buffer (NP0002) and transferred on a 0.2 µm
nitrocellulose membrane. Membranes were blocked with 5%
milk in TBS supplemented with Tween-20 (TBST, 10 mM Tris-
HCl, 150 mM NaCl, 0.1% Tween-20, pH 8.0) for 1 h at RT.
Thereafter, membranes were incubated overnight at 4◦C with
the following primary antibodies: 1:1,000 anti-NLRP3 (D4D8T,
Cell Signaling), 1:500 anti-LRRK2 (75–188, UC Davis), 1:10,000
anti-β-actin (A1978, Sigma). On the next day, membranes were
washed three times in TBST and incubated with the respective
secondary antibodies for 1 h at RT. Immunoreactivity was
detected by enhanced chemiluminescence reaction (ECL select
Western blotting detection reagent, GE Healthcare) or near-
infrared detection (Odyssey, Li-COR).
Immunocytochemistry and Image
Analysis
IPSCs and microglia were fixed in 4% PFA (Thermo Fisher
Scientific, Alfa Aesar J61899) for 15 min and washed twice with
PBS (Westburg, LO BE17-513F). The cells were permeabilized
and blocked in PBS containing 0.25% Triton X-100 and 1%
BSA for 1 h at RT followed by overnight incubation with
primary antibodies: anti-Nanog (3580S, Bioke), anti-Sox2 (sc-
365823, Santa Cruz), anti-Oct4 (ab19857, Abcam), anti-Iba1
(ab5076, Abcam), anti-P2RY12 (APR-020-F, Alomone labs).
On the next day, cells were washed and incubated with the
corresponding secondary antibodies. Thereafter, another three
washing steps with PBS were completed and Hoechst was used
as a counterstain at 0.1 mg/ml for 15 min in PBS. To mount
the cover slips onto slides, Prolong Antifade mounting media
(Thermo Fisher Scientific) was used. Acquisition of microglia
images was performed using a Zeiss LSM 710 and Yokogawa
CV8000 microscope, and images of iPSC were acquired with a
Zeiss Axio Imager M2. All acquired images were normalized for
secondary-only antibody control, to confirm specificity of the
signal observed.
For quantitative image analysis, custom code was
implemented using MATLAB 2020a, and computations
were performed using the High-Performance Computing (HPC)
infrastructure of the University of Luxembourg (Varrette et al.,
2014). Briefly, the “ZymosanAreaByIba1Area” is the ratio
between Zymosan positive pixels and Iba1 positive pixels per
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field of view. Furthermore, the mean abundance of Iba1 has been
quantified as ratio of Iba1 area per nuclei count. The underlying
MATLAB code is available upon request.
Statistics
All experiments carried out using iPSC-derived microglia
were performed with 3–4 biological replicates. The data was
normalized by the average of values per replicate. For statistical
analyses, GraphPad Prism software (version 9) was used. To
evaluate the presence of outliers, we used the ROUT test. Two-
way ANOVA was used for grouped values. Differences were
considered significant (∗) when p-values were below 0.05.
RESULTS
Idiopathic Postmortem Midbrain Tissue
Is Exhibiting Increased Cytokine Gene
Expression
Studies implicating inflammatory cytokines in PD have been
mostly conducted on neurotoxin and genetic animal models,
or by analyzing peripheral blood samples and CSF from PD
patients (Badanjak et al., 2021). To further confirm if these
findings are indeed occurring in the brain of IPD patients, we
analyzed available transcriptomic datasets. The transcriptomics
data of human IPD and control SN revealed a significant
increase in IL1B and IL10 expression in the patient tissue
(FDR = 0.023; FDR = 0.0067, respectively) (Figure 1A
and Supplementary Table 1). A recent study showed that
inflammation is not only mediated by microglia but can also
be observed in neurons from an IPD mouse model (Panicker
et al., 2020). In order to understand whether the detected
immune signatures in the human SN are also cell-type specific,
we examined our midbrain snRNAseq dataset to obtain an
insight into transcriptional changes with single-cell resolution.
We confirmed that the expression of cytokines is specific
to microglia (Figure 1B). Further analysis of the microglia
population revealed higher expression and a larger percentage of




IPD patient and control microglia were generated using an
established protocol (van Wilgenburg et al., 2013; Haenseler et al.,
2017; Figure 2A). The available iPSC lines were characterized
by immunostaining with the stem cell markers Nanog, Sox2
and Oct4 (Figure 2B). Differentiation of iPSCs into microglia
was achieved with the addition of multiple factors throughout
the differentiation process (Figure 2A) to mimic microglia
development in the human embryo. The microglial identity
of cells was confirmed by positive expression of Iba1 and
purinergic receptor (P2RY12) (Figure 2C). Comparable Iba1
areas per nuclei suggest that the disease status of the investigated
lines did not have an impact on the differentiation procedure
(Figure 2D). Additionally, we wanted to functionally characterize
microglia cells by treating them with Zymosan bioparticles
and assessing their phagocytic ability. While both control and
IPD microglia were able to phagocyte the bioparticles, IPD
microglia had a higher capacity (mean: 0.02493, SD = 0.02472)
compared to control microglia (mean: 0.01606, SD = 0.01304;
ANOVA: ∗∗∗p = 0.0004). Furthermore, although the mean
phagocytic capacity after LPS treatment was not significantly
different between untreated and treated cells, IPD microglia had
a significantly higher uptake of Zymosan particles compared to
control cells upon addition of LPS (CTR/LPS mean: 0.01897,
SD = 0.01695; IPD/LPS mean: 0.02683, SD = 0.02835; ANOVA:
∗∗p= 0.0070) (Figure 3).




To test the transferability of our findings from postmortem
single-nuclei transcriptomics to live cells, we investigated the
gene expression of IL1B and IL10 in iPSC-derived IPD microglia.
Moreover, we quantified the mRNA and protein levels of
the NLRP3 inflammasome, the inflammatory pathway most
associated with chronic inflammation in PD. The priming step
in inflammasome assembly is frequently mimicked by LPS
FIGURE 1 | Cytokine expression in bulk RNA-seq and single-nuclei RNA-seq datasets. (A) Bulk analysis of SN tissue displays higher expression of IL1B and IL10 in
IPD (FDR = 0.023; FDR = 0.0067). (B) Single-nuclei analysis of the human midbrain shows that the overall expression of cytokines is higher in microglia (3903 cells)
than in neurons (5314 cells). (C) Cytokines are expressed in a large number of IPD and control microglia. Z-score-scaled average expression per cluster shows
higher levels in IPD compared to control microglia. “DotPlot” function (Seurat package) was used to visualize expression and percentage of cytokine-expressing
cells. ∗p < 0.05; ∗∗p < 0.01; IPD, idiopathic PD.
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FIGURE 2 | Characterization of cellular models used in the study. (A) Overview of the protocol used to derive microglia from iPSCs. (B) Immunostaining with Nanog,
Sox-2 and Oct-4, coupled with nuclear staining with Hoechst, confirmed the iPSC identity of our cells. Scale bar, 50 µm. (C) Terminally differentiated microglia were
confirmed to express the microglia-specific markers Iba1 and P2RY12. Scale bar, 30 µm. (D) Quantification of data from (C); no difference in Iba1 protein levels (Iba1
area was normalized for nuclei count); IPD, idiopathic PD; CTR, healthy control.
treatment (McKee and Coll, 2020). At baseline, IPD and control
microglia did not show significant differences (data not shown).
However, upon LPS treatment, the expression levels of IL1B
and IL10 increased significantly in both conditions compared
to the respective untreated cells (IL1B CTR/LPS fold mean:
1.558, SD = 0.117; ANOVA: ∗∗p = 0.0098; IPD/LPS fold mean:
3.880, SD = 0.323; ANOVA: ∗∗∗∗p < 0.0001; IL10 CTR/LPS fold
mean: 3.409, SD = 0.342, ANOVA: ∗∗∗∗p < 0.0001; IPD/LPS
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FIGURE 3 | Functional assessment of iPSC-derived microglia. (A) Representative immunostaining showing the functional ability of cultured control and IPD microglia
treated with Zymosan bioparticles. Scale bar, 50 µm. (B) Quantification of data from (A); IPD microglia have higher phagocytic capacity (Zymosan area was
normalized for Iba1 area) compared to control cells. ∗∗p < 0.01; ∗∗∗p < 0.001; IPD, idiopathic PD; CTRL, healthy control.
fold mean: 7.717, SD = 0.530, ANOVA: ∗∗∗∗p < 0.0001). When
comparing the treatment response between both conditions, IPD
microglia showed significantly higher IL1B and IL10 expressions
fold changes compared to control cells (IL1B LPS mean: 2.719,
SD = 1.642; ANOVA: ∗∗∗∗p < 0.0001; IL10 LPS mean: 5.563,
SD = 3.047, ANOVA: ∗∗∗∗p < 0.0001). Additionally, when
investigating NLRP3 expression, only IPD microglia showed
a significant upregulation upon LPS treatment, compared to
both untreated IPD cells (NLRP3 IPD/LPS fold mean: 3.984,
SD= 0.250; ANOVA: ∗∗∗∗p < 0.0001) and to LPS-treated healthy
microglia (NLRP3 LPS mean: 2.627, SD = 1.918; ANOVA:
∗∗∗∗p < 0.0001) (Figure 4A).
Furthermore, NLRP3 protein levels corroborated the gene
expression results. Again, both control and IPD microglia had
significantly higher NLRP3 protein levels upon LPS addition
compared to their respective basal levels (CTR/LPS fold mean:
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FIGURE 4 | Inflammatory phenotype and LRRK2 levels in iPSC-derived microglia. (A) IL1B and IL10 gene expression (normalized to ACTB) in control and IPD
microglia; a quantitative PCR showed higher gene expressions of IL1B and IL10 in IPD compared to control cells upon priming with LPS (100 ng/ml). Values are
represented as fold changes of untreated cells. (B) NLRP3 mRNA and protein levels (normalized to ACTB and β-actin, respectively) are increased in IPD microglia
compared to control cells upon priming with LPS (100 ng/ml). Values are represented as fold change of untreated cells. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗∗p < 0.0001; IPD,
idiopathic PD, NLRP3, NOD-, LRR-, and pyrin domain-containing protein 3.
1.866, SD = 0.254; IPD/LPS fold mean: 2.231, SD = 0.115;
ANOVA: ∗∗∗∗p < 0.0001). However, when comparing across
conditions, IPD microglia showed a significant upregulation
compared to treated control glia (LPS mean: 2.048, SD = 0.2585;
ANOVA: ∗p= 0.0416) (Figure 4B).
Downregulation of Leucine-Rich Repeat
Kinase 2 Upon Lipopolysaccharide
Treatment in Idiopathic Microglia
Leucine-rich repeat kinase 2 (LRRK2) is a protein implicated
in both the idiopathic and genetic forms of PD. It is highly
expressed in cells of the immune system and associated
with immune disorders (Van Limbergen et al., 2009; Umeno
et al., 2011) as well as infectious diseases (Zhang et al.,
2009; Weindel et al., 2020). Its pathogenic effects have been
extensively studied in the context of LRRK2-PD and in some
instances in IPD. Basal levels of LRRK2 expression were
significantly downregulated in IPD microglia (CTR mean:
1.355, SD = 0.136; IPD mean: 0.929, SD = 0.244; ANOVA:
∗p = 0.0226), while control cells had significantly lower
expression upon LPS treatment (CTR mean: 1.355, SD = 0.136;
CTR/LPS mean: 0.915, SD = 0.178; ANOVA: ∗p = 0.0186)
(Figure 5A). Furthermore, we investigated LRRK2 protein
levels in our iPSC-derived microglia and saw a non-significant
downregulation in untreated IPD microglia compared to controls
(CTR mean: 1.332, SD = 0.257; IPD mean: 0.615, SD = 0.425;
ANOVA: p = 0.0593). Moreover, after stimulating the cells
with LPS, IPD microglia had significantly less LRRK2 protein
compared to LPS-treated control glia (CTR/LPS mean: 1.649,
SD = 0.391; IPD/LPS mean: 0.402, SD = 0.215; ANOVA:
∗∗p= 0.0036) (Figure 5B).
DISCUSSION
Although the majority of PD cases suffer from the idiopathic form
of the movement disorder, the cause of neurodegeneration in
these individuals has not been extensively investigated. Genome
wide association studies (GWAS) identified over 40 PD risk loci,
the majority of which overlaps with known autosomal dominant
PD genes, most notably SNCA and LRRK2, while other studies
revealed the presence of heterozygous variants in autosomal
recessively inherited PD genes (Simón-Sánchez et al., 2009; Nalls
et al., 2014; Zeng et al., 2018; Germer et al., 2019; Lai et al., 2020).
The main difficulty scientists are facing when studying IPD is the
heterogeneous nature of the disease, which is further exacerbated
by a plethora of environmental and epigenetic influences.
Inflammation has been considered a hallmark of PD since
the late 1980’s, when an upregulation of reactive microglia
was first seen in patient brain tissue samples (McGeer et al.,
1988). Positron emission tomography (PET) imaging dyes, which
allow visualizing activated microglia in vivo over time, have
been tested as biomarkers for disease progression (Gerhard
et al., 2006; Terada et al., 2016; Roussakis and Piccini, 2018).
Unfortunately, however, the findings from PET studies have
not been successfully transferred to the clinic and the exact
molecular mechanisms triggering neuroinflammation in PD
currently remain elusive.
Thus, in this study, we investigated patient-derived microglia
to explore the inflammatory component of IPD. First, we
made use of publicly available transcriptomic data from
nigral postmortem tissue to assess the expression of different
cytokines in IPD patients compared to age-matched controls.
Previous reports established certain secreted cytokines as reliable
biomarkers in serum and plasma of PD patients, among them
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FIGURE 5 | LRRK2 levels in iPSC-derived microglia. (A) IPD microglia have a significant decrease of LRRK2 expression at basal level (normalized to ACTB). (B) IPD
microglia show a significant downregulation of total LRRK2 protein levels (normalized to β-actin) compared to control cells upon LPS treatment only. ∗p < 0.05;
∗∗p < 0.01; IPD, idiopathic PD; LRRK2, Leucine-rich repeat kinase 2.
IL-1β, IL-18, IL-6, IL-10, IL-8, TNF-α (Nagatsu et al., 2000;
Brodacki et al., 2008; Qin et al., 2016). In line with these
studies, our meta-analysis of published brain SNpc case-control
transcriptomics datasets indicated elevated levels of IL10 and
IL1B in IPD patients.
To explore the cellular origin of this upregulation in IPD, we
made use of our previously generated snRNAseq dataset from
midbrain IPD and control tissue. Multiple cytokines, including
IL10 and IL1B, were predominantly expressed in microglia. This
is in accordance with microglia acting as the main player of the
immune system in the CNS. Moreover, in the same published
dataset, we observed an increase in the microglia number as
well as morphological alterations, indicative of an activated state,
in IPD patients (Smajić et al., 2020). Next, to corroborate our
findings from homogenized SN tissue, we investigated whether
any of the aforementioned cytokines show an IPD-specific
expression pattern in microglia. While we observed an increase
in the expression of all investigated candidates in the patient
compared to control cells, the levels of IL10, IL18, and IL1B were
the most abundant.
Albeit informative, these postmortem results may be
confounded by the fact that they only represent the molecular
situation during the latest stage of the disease. Thus, to study
inflammatory phenotypes and pathways in an in vitro IPD
model, we differentiated microglia from control and patient-
derived iPSCs using a published protocol (van Wilgenburg et al.,
2013; Haenseler et al., 2017). While cultured IPD microglia did
not show altered morphology (data not shown), we observed
elevated phagocytosis in these cells indicative of overactive
immune function. Phagocytosis is an integral part of microglial
homeostatic function, and is not only involved in the recognition
of self and non-self threats, but also in the engulfment of synaptic
elements and the pruning process. Furthermore, enhanced and
uncontrolled clearance is contributing to synaptic degeneration.
Indeed, multiple PD studies showed loss of presynaptic terminals
and synaptic changes in PD patient compared to control brains
(Delva et al., 2020; Matuskey et al., 2020). It is also worth noting
that disrupting the phagocytic ability of mouse glia was sufficient
to rescue the neuronal degeneration phenotype observed in
these animals after LPS injection (Bodea et al., 2014). Since we
observed the differences in phagocytosis already at basal level,
one may speculate that the genetic background in IPD glia
contributes to the development of the disease. However, it is
still unclear whether overactive, defective or perturbed uptake
triggers PD pathogenesis (Janda et al., 2018).
To further validate our findings from postmortem tissue,
we analyzed different inflammasome components in the iPSC-
derived microglia cultures. IPD microglia were more reactive
after priming with LPS, as indicated by enhanced expressions
of IL1B and IL10, and higher mRNA and protein levels of
NLRP3 compared to treated control cells. Higher levels of IL1B
and NLRP3 in IPD microglia indicate a stronger priming step,
which is necessary for downstream inflammasome activation
and immune response. While we are the first to show NLRP3
dysregulation in iPSC-derived IPD microglia, our results are in
agreement with findings from genetic PD models. Specifically,
α-synuclein fibrils were shown to induce NLRP3 activation, and
loss of the PD-associated protein Parkin triggered the release
of mitoDAMPs into the cytosol, which in turn activated the
NLRP3 inflammasome in mice (Zhong et al., 2016; Gordon
et al., 2018; Ji et al., 2020; Pike et al., 2021). Moreover, NLRP3
was shown to regulate IL10 levels in mice macrophages, with
IL10 production being decreased in NLRP3−/− mice (Gurung
et al., 2015; Kobayashi et al., 2016). This is consistent with our
observation of IL10 and NLRP3 co-regulation. In line with a
biomarker study in serum, IPD patients had higher levels of
IL-10 compared to healthy individuals (Rentzos et al., 2009).
Furthermore, while the relationship of IL-1β and IL-10 has
not been extensively studied in the context of PD, there are
reports showing that, under inflammatory conditions, IL-10
selectively inhibits the release of IL-1β (Sun et al., 2019). Patient-
derived microglia will be a useful model to explore the molecular
mechanisms linking IL-10 and IL-1β in PD in more detail.
Further of interest with regard to inflammation in genetic but
also IPD is the kinase LRRK2. Affected individuals harboring
mutations in LRRK2 closely mirror the clinical picture of IPD
patients (Tolosa et al., 2020) with kinase activity dysregulation
being a shared feature of both forms of the disease. Due to its
high abundance in immune cells, researchers have speculated
that LRRK2 may be crucially involved in the regulation of
neuroinflammatory processes (Gardet et al., 2010; Di Maio
et al., 2018; Fyfe, 2018). Studies investigating LRRK2 expression
in IPD brain tissue showed a significant downregulation in
dopaminergic neurons, which may contribute to the pathology
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of the movement disorder (Simunovic et al., 2009; Sharma et al.,
2011; Yılmazer et al., 2021). In agreement with these reports,
we detected significantly reduced LRRK2 expression and a trend
toward lower LRRK2 protein abundance in IPD patient microglia
at baseline. Inflammatory insults exacerbated this phenotype,
leading to a further reduction in LRRK2 protein levels in the IPD
patient-derived cells. However, the exact pathways connecting
LRRK2 downregulation to microglia dysfunction in IPD warrant
further investigation.
Taken together, inspired by published biomarker studies, we
investigated inflammatory phenotypes in different models of IPD.
In both, nigral and midbrain RNAseq datasets, we observed a
disease-specific upregulation of IL10 and IL1B. Furthermore,
from our postmortem single-cell results, we derived that this
overexpression predominantly stems from microglia. Next, to
test whether we could reproduce this phenotype in a dish,
we generated iPSC-derived IPD microglia. Further implicating
IL10 and IL1B, in IPD, the expression of these cytokines
was also enhanced in patient microglia upon LPS treatment.
Finally, we identified an upregulation of NLRP3 on RNA and
protein level, corroborating our findings concerning IL10 and
IL1B. However, in light of the variability of sporadic PD, our
results from a small sample may only be representative for
a subset of IPD cases, warranting validation studies in larger
cohorts. Moreover, while our study highlights the relevance of
microglia in IPD, further experiments will be needed to decipher
the exact pathways triggering neuroinflammation in sporadic
PD patients.
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(2021). Low Levels of LRRK2 Gene Expression are Associated with LRRK2
SNPs and Contribute to Parkinson’s Disease Progression. Neuromol. Med. 23,
292–304. doi: 10.1007/s12017-020-08619-x
Zeng, X.-S., Geng, W.-S., Jia, J.-J., Chen, L., and Zhang, P.-P. (2018). Cellular
and Molecular Basis of Neurodegeneration in Parkinson Disease. Front. Aging
Neurosci. 10:109. doi: 10.3389/fnagi.2018.00109
Zhang, F.-R., Huang, W., Chen, S.-M., Sun, L.-D., Liu, H., Li, Y., et al. (2009).
Genomewide association study of leprosy. N. Engl. J. Med. 361, 2609–2618.
Zhong, Z., Umemura, A., Sanchez-Lopez, E., Liang, S., Shalapour, S., Wong, J., et al.
(2016). NF-κB Restricts Inflammasome Activation via Elimination of Damaged
Mitochondria. Cell 164, 896–910. doi: 10.1016/j.cell.2015.12.057
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Publisher’s Note: All claims expressed in this article are solely those of the authors
and do not necessarily represent those of their affiliated organizations, or those of
the publisher, the editors and the reviewers. Any product that may be evaluated in
this article, or claim that may be made by its manufacturer, is not guaranteed or
endorsed by the publisher.
Copyright © 2021 Badanjak, Mulica, Smajic, Delcambre, Tranchevent, Diederich,
Rauen, Schwamborn, Glaab, Cowley, Antony, Pereira, Venegas and Grünewald.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner(s) are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Cell and Developmental Biology | www.frontiersin.org 11 November 2021 | Volume 9 | Article 740758
